medicaid coverage glp 1 Indiana is expanding access to GLP-1s — the diabetes and weight loss medications — to members of the state's program. The expansion is part of a federal pilot to allow more 📢 New Resource Alert! We've

Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, et al

In conclusion, our study provides a rationale for the identification of l-carnitine as a potent therapeutic agent for the treatment of synovitis of KOA

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)

That case gets its own section below